Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929636 | 1.00 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DALOX5AP | |
| SCHEMBL6927006 | 1.00 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DALOX5AP | |
| SCHEMBL8344112 | 0.92 | PDE4B (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6923150 | 0.91 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DCTSD | |
| SCHEMBL6925796 | 0.91 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DCTSD | |
| SCHEMBL6923149 | 0.91 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DCTSD | |
| SCHEMBL6898320 | 0.87 | PDE4B (0.58) | PDE4APDE4BPDE4CPDE4DCTSD | |
| SCHEMBL12845204 | 0.83 | PDE4B (0.48) | PDE4APDE4BPDE4CPDE4DCTSD | |
| SCHEMBL6925141 | 0.82 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DCTSD | |
| SCHEMBL6925146 | 0.82 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518306-B1 | PDE4 inhibitors particularly in regards to treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2003-02-11 | — | — | US | claimed |
| EP-1202955-A4 | 1,4-SUBSTITUTED 4,4-DIARYL CYCLOHEXANES | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| WO-2003105902-A1 | TREATMENT FOR DEPRESSION AND ANXIETY BY THE COMBINATION OF A PDE IV INHIBITOR AND AN ANTIDEPRESSANT OR AN ANXIOLYTIC AGENT | PFIZER PRODUCTS INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003105815-A1 | COMBINATION OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | PFIZER PRODUCTS INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-6518306-B1 | PDE4 inhibitors particularly in regards to treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-1202955-A2 | 1,4-SUBSTITUTED 4,4-DIARYL CYCLOHEXANES | SmithKline Beecham Corporation (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010385-A2 | 1,4-SUBSTITUTED 4,4-DIARYL CYCLOHEXANES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-15 | — | — | WO | disclosed |